Skip to main content
SpringerLink
Log in

Matrix metalloproteinases in heart failure: evidence from experimental models

  • Chapter
Inflammation and Cardiac Diseases

Part of the book series: Progress in Inflammation Research ((PIR))

  • 117 Accesses

Abstract

The LV myocardial remodeling process invariably occurs with the development and progression of congestive heart failure (CHF). LV remodeling is a multi-cellular process that results in abnormalities in LV myocardial wall structure and chamber geometry. It is becoming appreciated that important changes occur within the extra-cellular matrix (ECM) of the myocardium and can contribute to the LV remodeling process. Moreover, it has become increasingly evident that the myocardial ECM is not a static structure, but rather a dynamic entity that may play a fundamental role in myocardial adaptation to a pathological stress and thereby facilitate remodeling. Specifically, in both human and animal studies, it has been reported that alterations in the collagen interface, both in structure and composition, occur within the LV myocardium, which in turn may influence LV geometry [1-5]. The myocardial ECM contains a fibrillar collagen network, a basement membrane, proteoglycans and glycosaminoglycans, and bioactive signaling molecules. The myocardial fibrillar collagens such as collagen Types I and III, ensure structural integrity of adjoining myocytes, provide the means by which myocyte shortening is translated into overall LV pump function and are essential for maintaining alignment of myofibrils within the myocyte through a collagen-integrin-cytoskeletal-myofibril relation. The ECM forms a continuum between different cell types within the myocardium and provides a structural supporting network in order to maintain myocardial geometry during the cardiac cycle. Specific and distinct changes occur within the ECM with each of the three main cardiac disease states which give rise to CHF: Myocardial infarction, severe LV hypertrophy, and the cardiomyopathies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sackner-Bernstein JD (2000) The myocardial matrix and the development and progression of ventricular remodeling. CurrCardiol Rep2 (2): 112–119

    Article  PubMed  CAS  Google Scholar 

  2. Spinale FG (2002) Matrix metalloproteinases; regulation and dysregulation in the failing heart.Circ Res90(5):520–530

    Article  PubMed  CAS  Google Scholar 

  3. Cluetjens JPM, Verluyten MJA, Smits JFM, Daemen MJAP (1995) Collagen remodeling after myocardial infarction in the rat heart.Am J Path147 (2): 325–338

    Google Scholar 

  4. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC, Cruickshank JM, Devereux, RB, Giles TD, Korsgaard N, Leier CV et al (1992) Remodeling and reparation of the cardiovascular system.J Am Coll Cardiol20: 3–16

    Article  PubMed  CAS  Google Scholar 

  5. Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling.J Am Coll Cardiol35: 569–582

    Article  PubMed  CAS  Google Scholar 

  6. Kim HE, Dalal SS, Young E, Legato MJ, Weisfeldt ML, D’Armiento J (2000) Disruption of the myocardial extracellular matrix leads to cardiac dysfunction.J Clin Invest106: 857–866

    Article  PubMed  CAS  Google Scholar 

  7. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L (1998) Time dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: Relation to ventricular and myocyte function.Circ Res82: 482–495

    Article  PubMed  CAS  Google Scholar 

  8. Spinale FG, Krombach RS, Coker ML, Mukherjee R, Thomas CV, Houck WV, Clair MJ, Kribbs SB, Johnson LL, Peterson JT (1999) Matrix metalloproteinase inhibition during developing congestive heart failure in pigs: Effects on left ventricular geometry and function.Circ Res85: 364–376

    Article  PubMed  CAS  Google Scholar 

  9. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, Lee RT (1999) Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice.Circulation99: 3063–3070

    Article  PubMed  CAS  Google Scholar 

  10. Roten L, Nemoto S, Simsic J, Coker ML, Rao V, Baicu S, Defreyte G, Soloway PJ, Zile MR, Spinale FG (2000) Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice.J Mol Cell Cardiol32: 109–120

    Article  PubMed  CAS  Google Scholar 

  11. Nagatomo Y, Carabello BA, Coker ML, McDermott PJ, Nemoto S, Hamawaki M, Spinale FG (2000) Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. AmJ Physiol278: H151–H161

    CAS  Google Scholar 

  12. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dsyspersin GD, Cleutjens JP, Shipley M, Angellilo A et al (1999) Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.Nat Med 5:1135–1142

    Article  PubMed  CAS  Google Scholar 

  13. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb A, Libby P et al (2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction.J Clin Invest106: 55–62

    Article  PubMed  CAS  Google Scholar 

  14. Creemers EEJM, Cleutjens JPM, Smits JFM, Daemen MJAP (2001) Matrix metalloproteinase inhibition after myocardial infarction. A new approach to prevent heart failure?Circ Res89: 201–210

    Article  PubMed  CAS  Google Scholar 

  15. Peterson JT, Hallak H, Johnson L, Li H, O’Brien PM, Sliskovic DR, Bocan TM, Coker ML, Etoh T, Spinale FG (2001) Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure.Circulation103: 2303–2309

    Article  PubMed  CAS  Google Scholar 

  16. Peterson TJ, Li H, Dillon L, Bryant JW (2000) Evolution of matrix metalloproteinase and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res46: 307–315

    Article  PubMed  CAS  Google Scholar 

  17. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ, Spinale FG (1998) Increased matrix metalloproteinase activity and selective up-regulation in LV myocardium from patients with end-stage dilated cardiomyopathy.Circulation97: 1708–1715

    Article  PubMed  CAS  Google Scholar 

  18. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ (2000) A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is up-regulated in heart failure.Circulation102: 1944–1949

    Article  PubMed  CAS  Google Scholar 

  19. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF (1996) Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy: Role of metalloproteinases and pyridinoline cross links. AmJ Path148:1639–1648

    PubMed  CAS  Google Scholar 

  20. Li YY, Feldman AM, Sun Y, McTiernan CF (1998) Differential expression of tissue inhibitors of metalloproteinases in the failing human heart.Circulation98: 1728–1734

    Article  PubMed  CAS  Google Scholar 

  21. Li YY, Feng Y, McTiernan CF, Pei W, Moravec CS, Wang P, Rosenblum W, Kormos RL, Feldman AM (2001) Down-regulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices.Circulation104: 1147–1152

    Article  PubMed  CAS  Google Scholar 

  22. Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, Spinale FG, Mann DL (2001) Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor.Circulation104: 826–831

    Article  PubMed  CAS  Google Scholar 

  23. Chancey AI, Brower GL, Peterson TJ, Janicki JS (2002) Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload.Circulation105: 1983–1988

    Article  PubMed  CAS  Google Scholar 

  24. Li H, Simon H, Bocan TM, Peterson JT (2000) MMP/TIMP expression in spontaneously hypertensive heart failure rats: The effect of ACE and MMP inhibition.Cardiovasc Res46: 298–306

    Article  PubMed  CAS  Google Scholar 

  25. Woessner FJ (1998) The matrix metalloproteinase family. In: Parks WC, Mecham RP (eds):Matrix metalloproteinases.Academic Press, San Diego, 1–141

    Chapter  Google Scholar 

  26. Woessner JF, Nagase H (2000) Introduction to the matrix metalloproteinases (MMPs). In:Matrix metalloproteinases and TIMPs.Oxford University Press, Oxford, 1–10

    Chapter  Google Scholar 

  27. Vu TH, Werb Z (2000) Matrix metalloproteinases: Effectors of development and normal physiology.Genes Dev14: 2123–2133

    Article  PubMed  CAS  Google Scholar 

  28. Nelson AR, Fingleton B, Rotherenberg ML, Matrisian LM (2000) Matrix metallopro-teinases: Biological activity and clinical implications.J Clin Oncol18: 1135–1149

    PubMed  CAS  Google Scholar 

  29. Hansen-Birkedal H, Moore WGI, Bodden MK, Windsor LJ, Hansen-Birkadal B, DeCarlo A, Engler JA (1993) Matrix metalloproteinases: A review.Crit Rev Oral Biol Med4: 197–250

    Google Scholar 

  30. McDonnell S, Morgan M, Lynch C (1999) Role of matrix metalloproteinases in normal and disease processes.Biochem Soc Trans27(4): 734–740

    PubMed  CAS  Google Scholar 

  31. Knauper V, Murphy G (1998) Membrane-type matrix metalloproteinases and cell surface-associated activation cascades for matrix metalloproteinases. In: WC Parks and RP Mecham (eds):Matrix metalloproteinases.Academic Press, London, 199–218

    Chapter  Google Scholar 

  32. Spinale FG (2002) Matrix metalloproteinases: Regulation and dysregulation in the failing heart.Circ Res90 (5): 520–530

    Article  PubMed  CAS  Google Scholar 

  33. Pfeffer MA, Braunwald E (1990) Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications.Circulation81: 1161–1172

    Article  PubMed  CAS  Google Scholar 

  34. Etoh T, Joffs C, Deschamps AM, Davis J, Dowdy K, Hendrick J, Baicu S, Mukherjee R, Manhaini M, Spinale FG (2001) Myocardial interstitial matrix metalloproteinase activity following acute myocardial infarction in pigs. AmJ Physiol281: H987–994

    CAS  Google Scholar 

  35. Dixon IMJ, Ju H, Reid NL, Scammell-La Fleur, Werner JP, Jasmin G (1997) Cardiac collagen remodeling in the cardiomyopathic Syrian hamster and the effect of losartan.J Mol Cell Cardiol29: 1837–1850

    Article  PubMed  CAS  Google Scholar 

  36. Mujumdar VS, Tyagi SC (1999) Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure.J Hyperten17: 261–270

    Article  CAS  Google Scholar 

  37. Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM, Lowry AS, Escobar GP, Lucas DG, Yarbrough WM et al (2003) Myocardial infarct expansion and matrix metalloproteinase inhibition.Circulation107 (4): 618–625

    Article  PubMed  CAS  Google Scholar 

  38. Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-Morrow L, Crawford J, Black S, Libby P, Mitchell PG, Lee RT (2002) Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction.Circulation15: 753–758

    Article  Google Scholar 

  39. Fini ME, Cook JR, Mohan R, Brinckerhoff CE (1998) Regulation of matrix metallo-proteinase gene expression. In: Parks WC, Mecham RP (eds):Matrix metalloproteinases.San Diego: Academic, 299–356

    Chapter  Google Scholar 

  40. Vincenti MP (2001) The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. In: Clark I (ed):Methods in molecular biology vol 151: Matrix metalloproteinase protocols. Humana Press Inc. Totawa NJ 121–148

    Google Scholar 

  41. Ries C, Petrides PE (1995) Cytokine regulation of matrix metalloproteinase activity and regulatory dysfunction in disease.Biol Chem376: 345–355

    CAS  Google Scholar 

  42. Bradham WS, Moe G, Wendt K, Konig A, Romanova M, Naik G, Spinale FG (2002) Tumor necrosis factor-alpha influences myocardial matrix metalloproteinases in experimental heart failure: Relationship to left ventricular remodeling.Am J Physiol282 (4): H1288–1295

    CAS  Google Scholar 

  43. Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B, Deswal A, Mann DL, Spinale FG (2002) Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.J Card Failure8 (6): 390–398

    Article  CAS  Google Scholar 

  44. Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA, Gearing AJH, Huxley P, Laber D, McCourt M et al. (1999) Preclinical and clinical studies of MMP inhibitors in cancer. NYAcad Sci878: 228–235

    Article  CAS  Google Scholar 

  45. Peterson JT, Hua L (2002) Matrix metalloproteinase inhibitor development for the treatment of heart failure.Drug Devel Res55: 29–44

    Article  CAS  Google Scholar 

  46. Levitt NC, Eskens FALM, O’Byrne KJ, Propper DJ, Denis LJ, Owen SJ, Choi L, Foekens JA, Wilner S, Wood JM et al (2001) Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MM1270 (CGS27023A), in patients with advanced solid cancer.Clin Cancer Res7: 1912–1922

    PubMed  CAS  Google Scholar 

  47. Brinckerhoff CE, Matrisian LM (2002) Matrix metalloproteinases: A tail of a frog that became a prince.Nat Rev3: 207–214

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiothoracic Surgery, Room 625, Strom Thurmond Research Building, 770 MUSC Complex, Medical University of South Carolina, 114 Doughty Street, Charleston, SC, 29425, USA

    Francis G. Spinale

Authors
  1. Francis G. Spinale
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmacology Department WP42-209, Merck Research Laboratories, 770 Sumneytown Pike, West Point, PA, 19486, USA

    Giora Z. Feuerstein

  2. Cardiovascular Medicine, Brigham and Women’s Hospital, 221 Longwood Avenue EBRC 307, Boston, MA, 02115, USA

    Peter Libby

  3. Winters Center for Heart Failure Research, 6565 Fannin MS 524, Houston, TX, 77030, USA

    Douglas L. Mann

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Basel AG

About this chapter

Cite this chapter

Spinale, F.G. (2003). Matrix metalloproteinases in heart failure: evidence from experimental models. In: Feuerstein, G.Z., Libby, P., Mann, D.L. (eds) Inflammation and Cardiac Diseases. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8047-3_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8047-3_5

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9419-7

  • Online ISBN: 978-3-0348-8047-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation